<PAGE>

                        SECURITIES AND EXCHANGE COMMISSION
                             Washington, D. C. 20549
                                   FORM 10-QSB

 [x] Quarterly report under Section 13 or 15(d) of the Securities Exchange Act
     of 1934.

     For the quarterly period ended June 30, 2003.

 [ ] Transition report under Section 13 or 15(d) of the Securities Exchange
     Act of 1934.

     For the transition period from __________ to _____________


                         Commission File Number: 0-28666


                         AMERICAN BIO MEDICA CORPORATION
        -----------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)


                New York                                  14-1702188
     -------------------------------                ---------------------
     (State or other jurisdiction of                   (I.R.S. Employer
      incorporation or organization)                  Identification No.)


                   122 Smith Road, Kinderhook, New York 12106
                   -------------------------------------------
                    (Address of principal executive offices)


                                  800-227-1243
                           ---------------------------
                           (Issuer's telephone number)


      Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

      Yes [X]    No [ ]

     State the number of shares outstanding of each of the issuer's classes of
common equity as of the latest practicable date:

     20,638,548 Common Shares as of August 12, 2003



     Transitional Small Business Disclosure Format: Yes [ ]  No [X]


<PAGE>


                                     PART I

                              FINANCIAL INFORMATION

                         American Bio Medica Corporation
                                 Balance Sheets
<TABLE>
<CAPTION>

                                                                            June 30,
                                                                              2003              December 31,
                                                                          (Unaudited)               2002
                                                                        -----------------    -------------------
                               Assets
<S>                                                                           <C>                  <C>
Current assets:
      Cash and cash equivalents                                               $  201,000           $    231,000
      Accounts receivable, net of allowance of $70,000 at June 30,
       2003 and December 31, 2002                                              1,750,000              1,105,000
      Inventory                                                                2,420,000              2,795,000
      Prepaid and other current assets                                           102,000                 60,000
                                                                              ----------           ------------

Total current assets                                                           4,473,000              4,191,000
Property, plant and equipment, net                                             1,371,000              1,457,000
                                                                              ----------           ------------

Total Assets                                                                  $5,844,000           $  5,648,000
                                                                              ==========           ============


                Liabilities and Stockholders' Equity

Current liabilities:
      Accounts payable                                                        $  722,000           $    908,000
      Accrued liabilities                                                        502,000                513,000
      Current portion of mortgages and notes payable and capital
       lease obligations                                                         143,000                184,000
                                                                              ----------           ------------

Total current liabilities                                                      1,367,000              1,605,000

Long term portion of mortgages payable                                           666,000                673,000
Long term portion of unearned grant                                               75,000                 50,000
                                                                              ----------           ------------

Total liabilities                                                              2,108,000              2,328,000
                                                                              ----------           ------------

Stockholders' equity:
    Preferred stock; par value $.01 per share;
    5,000,000 shares authorized; none issued and outstanding
    Common stock; par value $.01 per share; 50,000,000
    shares authorized; 20,609,548 shares issued and outstanding
    at June 30, 2003 and December 31, 2002
                                                                                 206,000                206,000
Additional paid-in capital                                                    17,788,000             17,788,000
Accumulated deficit                                                          (14,019,000)           (14,435,000)
Treasury stock; 225,000 shares                                                  (239,000)              (239,000)
                                                                              ----------           ------------

Total stockholders' equity                                                     3,736,000              3,320,000
                                                                              ----------           ------------

Total liabilities and stockholders' equity                                    $5,844,000           $  5,648,000
                                                                              ==========           ============
</TABLE>

                 See accompanying notes to financial statements


                                       2

<PAGE>



                                    American Bio Medica Corporation
                                        Statements of Operations
                                              (Unaudited)
<TABLE>
<CAPTION>

                                                                           For The Six Months Ended
                                                                                   June 30,
                                                                       ---------------------------------
                                                                          2003                  2002
                                                                       -----------          ------------

<S>                                                                     <C>                  <C>
Net sales                                                               $5,820,000           $ 4,963,000
Cost of goods sold                                                       2,588,000             2,211,000
                                                                       -----------           -----------
Gross profit                                                             3,232,000             2,752,000
                                                                       -----------           -----------

Operating expenses:
    Research and development                                               339,000               169,000
    Selling and marketing                                                1,314,000             1,142,000
    General and administrative                                           1,321,000             1,156,000
                                                                       -----------           -----------
                                                                         2,974,000             2,467,000
                                                                       -----------           -----------
Operating income                                                           258,000               285,000
                                                                       -----------           -----------

Other income (expense):
   Other income                                                            198,000
   Interest income                                                          10,000                45,000
   Interest expense                                                        (49,000)              (24,000)
                                                                       -----------           -----------
                                                                           159,000                21,000
                                                                       -----------           -----------
Income before provisions for income taxes                                  417,000               306,000
Provision for (benefit from) income taxes                                        0                     0
                                                                       -----------           -----------
Net income                                                              $  417,000           $   306,000
                                                                       ===========           ===========

Basic and diluted income per common share                               $     0.02           $      0.01
                                                                       ===========           ===========
Weighted average shares outstanding  -
   basic                                                                20,609,548            20,609,548
Dilutive effect of stock options and warrants                              461,227               756,563
                                                                       -----------           -----------
Weighted average shares outstanding -
   diluted                                                              21,070,775            21,366,111
                                                                       ===========           ===========
</TABLE>



                 See accompanying notes to financial statements


                                       3
<PAGE>






                                    American Bio Medica Corporation
                                        Statements of Operations
                                              (Unaudited)
<TABLE>
<CAPTION>

                                                                          For The Three Months Ended
                                                                                   June 30,
                                                                       ---------------------------------
                                                                           2003                 2002
                                                                       -----------          ------------

<S>                                                                    <C>                  <C>
Net sales                                                              $ 3,171,000          $  2,710,000
Cost of goods sold                                                       1,418,000             1,226,000
                                                                       -----------          ------------

Gross profit                                                             1,753,000             1,484,000
                                                                       -----------          ------------

Operating expenses:
    Research and development                                               133,000                37,000
    Selling and marketing                                                  694,000               608,000
    General and administrative                                             660,000               593,000
                                                                       -----------          ------------
                                                                         1,487,000             1,238,000
                                                                       -----------          ------------

Operating income                                                           266,000               246,000
                                                                       -----------          ------------

Other income (expense):
   Other income                                                            186,000
   Interest income                                                           3,000                18,000
   Interest expense                                                        (31,000)              (12,000)
                                                                       -----------          ------------
                                                                           158,000                 6,000
                                                                       -----------          ------------
Income before provisions for income taxes                                  424,000               252,000
Provision for (benefit from) income taxes                                        0                     0
                                                                       -----------          ------------
Net income                                                             $   424,000          $    252,000
                                                                       ===========          ============

Basic and diluted income per common share                              $      0.02          $       0.01
                                                                       ===========          ============

Weighted average shares outstanding  -
   basic                                                                20,609,548            20,609,548
Dilutive effect of stock options and warrants                              250,652             1,237,606
                                                                       -----------          ------------
Weighted average shares outstanding -
   diluted                                                              20,860,200            21,847,154
                                                                       ===========          ============
</TABLE>

                 See accompanying notes to financial statements

                                       4
<PAGE>






                         American Bio Medica Corporation
                            Statements of Cash Flows
                                   (Unaudited)
<TABLE>
<CAPTION>

                                                                                                For The Six Months Ended
                                                                                                          June,
                                                                                             -------------------------------
                                                                                                2003                 2002
                                                                                             ----------           ----------
<S>                                                                                          <C>                  <C>
Cash flows from operating activities:
 Net income                                                                                  $  417,000           $  306,000
 Adjustments to reconcile net income to net cash provided by
  (used in) operating activities:
     Depreciation                                                                                90,000               75,000
     Non cash compensation expense                                                                                    16,000
     Accrued interest, related party                                                                                 (26,000)
     Gain on sale of land                                                                       (30,000)
     Changes in:
       Accounts receivable                                                                     (645,000)            (485,000)
       Inventory                                                                                374,000              383,000
       Prepaid expenses and other current assets                                                (42,000)              43,000
       Restricted cash                                                                                               106,000
       Accounts payable                                                                        (186,000)            (171,000)
       Accrued liabilities                                                                      (11,000)             (34,000)
       Customer advance deposits                                                                                     (81,000)
                                                                                             ----------           ----------
         Net cash provided by/(used in) operating activities                                    (33,000)             132,000
                                                                                             ----------           ----------

Cash flows from investing activities:
  Purchase of property, plant and equipment                                                    (123,000)             (43,000)
  Sale of land                                                                                  150,000
                                                                                             ----------           ----------
         Net cash provided by/(used in) investing activities                                     27,000              (43,000)
                                                                                             ----------           ----------

Cash flows from financing activities:
  Proceeds from grant                                                                            25,000               50,000
  Proceeds from sale of treasury stock                                                                               111,000
  Debt payments                                                                                 (74,000)              (8,000)
  Capital lease payments                                                                         (7,000)             (10,000)
  Proceeds from line of credit                                                                   40,000               20,000
  Line of credit payments                                                                        (8,000)              (3,000)
                                                                                             ----------           ----------
         Net cash provided by/(used in) financing activities                                    (24,000)             160,000
                                                                                             ----------           ----------

Net increase/(decrease) in cash and cash equivalents                                            (30,000)             249,000
Cash and cash equivalents - beginning of period                                                 231,000              288,000
                                                                                             ----------           ----------

Cash and cash equivalents - end of period                                                    $  201,000           $  537,000
                                                                                             ==========           ==========
Supplemental disclosures of cash flow information
 Cash paid during year for:
      Interest                                                                               $   49,000           $   13,000

</TABLE>
                 See accompanying notes to financial statements

                                       5
<PAGE>



Notes to financial statements (unaudited)

                                  June 30, 2003

Note A - Basis of Reporting

         The accompanying unaudited financial statements have been prepared in
accordance with accounting principles generally accepted in the United States of
America for interim financial information and with the instructions to Form
10-QSB. Accordingly, they do not include all of the information and footnotes
required by accounting principles generally accepted in the United States of
America for complete financial statements. In the opinion of management, such
statements include all adjustments (consisting only of normal recurring items),
which are considered necessary for a fair presentation of the financial position
of American Bio Medica Corporation (the "Company" or "ABMC") at June 30, 2003,
and the results of its operations, and cash flows for the six-month and
three-month periods ended June 30, 2003 and 2002. The results of operations for
the six-month and three-month periods ended June 30, 2003 are not necessarily
indicative of the operating results for the full year. These financial
statements should be read in conjunction with the Company's audited financial
statements and related disclosures for the year ended December 31, 2002 included
in the Company's Form 10-KSB.

         During the year ended December 31, 2002, the Company earned net income
of $719,000 from net sales of $10,312,000, and had net cash outflows from
operating activities of $400,000. During the six months ended June 30, 2003, the
Company earned a net income of $417,000 from net sales of $5,820,000. Included
in 2003 net income is $185,000 from the release of an accrual related to a
royalty agreement executed in 1998 and terminated by mutual agreement in the
second quarter of 2003. Net sales in the three months ended June 30, 2003 were
$3,171,000, which resulted in net income of $424,000, including the $185,000
accrual reversal previously mentioned. The Company had net cash used in
operating activities of $33,000 for the first six months of 2003 primarily as
the result of accounts receivable increases and inventory decreases. The Company
continued to take steps to improve its financial prospects including focusing on
research and development and sales and marketing, continued development of new
products, continued evaluation of a potential "CLUB-DRUG" panel, entering into
an agreement with an unaffiliated third party to develop test components for an
HIV test, and other measures to enhance profit margins.

         The Company's continued existence is dependent upon several factors,
including its ability to raise revenue levels and reduce costs to generate
positive cash flows, and to sell additional shares of the company's common stock
to fund operations, if necessary.


NEW ACCOUNTING STANDARDS

         In June 2001, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 143, Accounting for
Asset Retirement Obligation. SFAS No. 143 requires entities to record the fair
value of a liability for an asset retirement obligation in the period in which
it is incurred. When the liability is initially recorded, an entity capitalizes
a cost by increasing the carrying amount of the long-lived asset. Over time, the
liability is accreted to its present value each period and the capitalized cost
is depreciated over the useful life of the related asset. Upon settlement of the
liability, an entity either settles the obligation for its recorded amount or
incurs a gain or loss upon settlement. SFAS No. 143 is effective for fiscal
years beginning after June 15, 2002. The adoption of this Statement is not
expected to have a material impact on the Company's financial statements.

                                       6
<PAGE>

         In July 2002, the FASB issued SFAS No. 146, Accounting for Costs
Associated with Exit or Disposal Activities. SFAS No. 146 addresses financial
accounting and reporting for costs associated with exit or disposal activities
and nullifies Emerging Issues Task Force (EITF) Issue No. 94-3, Liability
Recognition for Certain Employee Termination Benefits and Other Costs to Exit an
Activity (including Certain Costs Incurred in a Restructuring). This Statement
is effective for exit and disposal activities initiated after December 31, 2002.
The adoption of this Statement did not have a material impact on the Company's
financial statements.

         In November 2002, the FASB issued FASB Interpretation No. 45,
Guarantor's Accounting and Disclosure Requirements for Guarantees, Including
Indirect Guarantees of Indebtedness of Others, an interpretation of FASB
Statement No. 5, 57, and 107 and Rescission of FASB Interpretation No. 34 ("FIN
45"). FIN 45 clarifies the requirements of SFAS No. 5, Accounting for
Contingencies, relating to the guarantor's accounting for, and disclosure of,
the issuance of certain types of guarantees. FIN 45 requires that upon issuance
of a guarantee, the guarantor must recognize a liability for the fair value of
the obligation it assumes under that guarantee. FIN 45 specifically excludes
certain guarantee contracts from its scope. Additionally, certain guarantees are
not subject to FIN 45's provisions for initial recognition and measurement but
are subject to its disclosure requirements. The initial recognition and
measurement provisions are effective for guarantees issued or modified after
December 31, 2002. The disclosure requirements are effective for our annual
financial statements for the year ended December 31, 2002. The Company has
adopted the provisions of this statement, which did not have a material impact
on its financial statements.

             In December 2002, the FASB issued SFAS No. 148, Accounting for
Stock Based Compensation--Transition and Disclosure, an amendment to FASB
Statement No. 123. This Statement amends SFAS No. 123, Accounting for
Stock-Based Compensation, to provide alternative methods of transition for a
voluntary change to the fair value based method of accounting for stock-based
employee compensation. In addition, this Statement amends the disclosure
requirements of Statement No. 123 to require prominent disclosures in both
annual and interim financial statements about the method of accounting for
stock-based employee compensation and the effect of the method used on reported
results. Finally, SFAS No. 148 amends APB Opinion No. 28, Interim Financial
Reporting, to require disclosure about those effects in interim financial
reporting. For entities that voluntarily change to the fair value based method
of accounting for stock-based employee compensation, the transition provisions
are effective for fiscal years ending after December 15, 2002. For all other
companies, the disclosure provisions and the amendment to APB No. 28 are
effective for interim periods beginning after December 15, 2002. The following
pro forma information gives effect to fair value of the options on the date of
grant using the Black-Scholes option-pricing model with the following
assumptions: dividend yield of 0%, volatility ranging from 84% to 85% for 2003
and 87% to 90% for 2002, risk free interest rates of ranging from 4.69% to 4.98%
for 2003 and 4.98% - 6.04% for 2002, and an expected life of 10 years for both
2003 and 2002. The pro-forma net income represents three months amortization of
expense associated with the option grants.
<TABLE>
<CAPTION>

                                                 Six months              Six months
                                                   ended                    ended
                                                  June 30,                 June 30,
                                                   2003                      2002
                                                ------------------------------------
<S>                                             <C>                      <C>
     Net Income/(loss):
           As reported                          $  417,000               $   306,000
           Pro forma                            $  235,000               $   137,000
     Basic and fully diluted income/(loss)
       per share
           As reported                              $  .02                     $ .01
           Pro forma                                $  .01                     $ .01

</TABLE>

                                       7
<PAGE>

         In January 2003, the FASB issued FASB Interpretation No. 46,
Consolidation of Variable Interest Entities ("FIN 46"). FIN 46 requires a
variable interest entity to be consolidated by a company if that company is
subject to a majority of the risk of loss from the variable interest entity's
activities or entitled to receive a majority of the entity's residual returns or
both. FIN 46 also requires disclosures about variable interest entities that a
company is not required to consolidate but in which it has a significant
variable interest. The consolidation requirements of FIN 46 apply immediately to
variable interest entities created after January 31, 2003. The consolidation
requirements apply to existing entities in the first fiscal year or interim
period beginning after June 15, 2003. Certain of the disclosure requirements
apply in all financial statements issued after January 31, 2003, regardless of
when the variable interest entity was established. The Company does not believe
the adoption of this Statement will have a material impact on its financial
statements.

        In April 2003, the FASB issued SFAS No. 149, Amendment of Statement 133
on Derivative Instruments and Hedging Activities. SFAS No. 149 amends and
clarifies financial accounting and reporting for derivative instruments,
including certain derivative instruments embedded in other contracts and for
hedging activities under FASB Statement No. 133, Accounting for Derivative
Instruments and Hedging Activities. This Statement is effective for contracts
entered into or modified after June 30, 2003. The Company does not believe the
adoption of this Statement will have a material impact on its financial
statements.

         In May 2003, the FASB issued SFAS No. 150, Accounting For Certain
Financial Instruments with Characteristics of both Liabilities and Equity. The
Statement improves the accounting for certain financial instruments that, under
previous guidance, issuers could account for as equity. The new Statement
requires that those instruments be classified as liabilities in statements of
financial position. This Statement is effective for all financial instruments
entered into or modified after May 31, 2003. The Company does not believe the
adoption of this Statement will have a material impact on its financial
statements.

Note B - Net Income Per Common Share

         Basic net income or loss per share is calculated by dividing the net
income or loss by the weighted average number of outstanding common shares
during the period. Diluted net income or loss per share includes the weighted
average dilutive effect of stock options and warrants.

         Potential common shares outstanding as of June 30, 2003 and 2002:

                                          June 30, 2003         June 30, 2002
                                          -------------         -------------
                Warrants                    2,651,703             2,651,703
                Options                     5,940,000             5,063,250

         For the three months and six months ended June 30, 2003 the number of
securities not included in the dilutive EPS, because the effect would have been
anti-dilutive, were 5,433,920 and 3,298,420 respectively. For the three months
and six months ended June 30, 2002 the number of securities not included in the
dilutive EPS, because the effect would have been anti-dilutive, were 2,988,670
and 3,018,670 respectively.

Note C - Litigation

         The Company has no pending litigation as of the date of this report.

Note D - Sale of Land

         On March 31, 2003 the Company sold approximately 85 acres of land at
its Kinderhook headquarters for $150,000 recognizing a gain of $30,000.


                                       8
<PAGE>

Note E - Reclassifications

         Certain items have been reclassified to conform to the current
presentation.


Item 2. Management's Discussion and Analysis or Plan of Operation

         MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS FOR THE SIX MONTHS AND THREE MONTHS ENDED JUNE 30, 2003 AND 2002

         The following discussion of the Company's financial condition and the
results of operations should be read in conjunction with the Financial
Statements and Notes thereto appearing elsewhere in this document.

          The Private Securities Litigation Reform Act of 1995 provides a safe
harbor for forward-looking statements. In order to comply with the terms of the
safe harbor, the Company notes that in addition to the description of historical
facts contained herein, this report contains certain forward-looking statements
that involve risks and uncertainties as detailed herein and from time to time in
the Company's other filings with the Securities and Exchange Commission and
elsewhere. Such statements are based on management's current expectations and
are subject to a number of factors and uncertainties, which could cause actual
results to differ materially from those, described in the forward-looking
statements. These factors include, among others: (a) the Company's fluctuations
in sales and operating results; (b) risks associated with international
operations; (c) regulatory, competitive and contractual risks; (d) product
development risks; and (e) the ability to achieve strategic initiatives,
including but not limited to the ability to achieve sales growth across the
business segments through a combination of enhanced sales force, new products,
and customer service.

Critical accounting policies

         There have been no significant changes to the Company's critical
accounting policies, which are included in the Company's 10KSB filing for the
year ended December 31, 2002, during the six months ended June 30, 2003.

         The Company has entered into several arrangements with third parties
that have agreed to fund Research and Development activities. The arrangements
include milestones that must be achieved to receive payment. The Company records
revenue based upon the lesser of costs incurred to date, or the milestone value
(for the milestone value to be used, the milestone must be achieved). In the
first six months of 2003 the Company recognized sales and cost of sales totaling
$60,000 from two separate arrangements for the performance of Research and
Development activities.

Results of operations for the six months ended June 30, 2003 as compared to the
six months ended June 30, 2002

         Net sales were $5,820,000 for the six months ended June 30, 2003 as
compared to $4,963,000 for the six months ended June 30, 2002, representing an
increase of $857,000 or 17.3%. Direct sales, telemarketing sales and
international sales continued as the primary sources of sales contributing
approximately $4,872,000 or 83.7% of the net sales for the first six months of
2003 compared to $3,462,000 or 69.8% of the net sales for the same period in
2002. During the six months ended June 30, 2003, the Company continued its
extensive program to market and distribute its primary product lines, the Rapid
Drug Screen(R) and Rapid One(R), in addition to its saliva based test, the
Oralstat(R) and its recently developed Rapid Tec(R) series.


                                       9
<PAGE>

         The Company continued its programs for the development of diagnostic
tests or test components using immunoassay lateral flow technology to diversify
its product line into the areas of veterinary medicine, mycotoxin detection, and
tuberculosis. In addition, components for a HIV test are being developed for a
third party and new drugs of abuse tests are being explored. The Company also
signed agreements for the purchase and sale of the CA 2000 Alcohol Analyzer, a
digital analyzer suitable for field use for the detection of alcohol via breath
analysis. Finally, the Company entered into an agreement with a manufacturer of
alcohol and adulterant tests to further expand and enhance its product lines.
Management believes that sales from its urine based drug test kits and the
OralStat saliva based test will continue to grow as a result of its focus on the
core business and renewed focus in marketing, and future sales will increase
from new product development.

        Cost of goods sold for the six months ended June 30, 2003 was $2,588,000
or 44.5% of net sales as compared to $2,211,000 or 44.5% of net sales for the
six months ended June 30, 2002. The increase in cost of goods sold is
commensurate with the increase in sales. Gross margins remained consistent year
to year at 55.5%; however, the current year sales and cost of sales include
amounts billed to entities for which the Company performed R&D services, which
were not billed in the prior year. In 2003 sales and cost of sales include
$60,000 for amounts billed to entities for which the Company performed R&D
services. Gross margins net of amounts billed for R&D work are 56.1% in 2003 and
55.5% for 2002. The cost of labor and materials has remained relatively
consistent and the Company continued its efforts to control the costs to produce
its product.

         Operating expenses increased 20.6% to $2,974,000 in first six months of
2003 as compared to $2,467,000 in the same period in 2002. This increase of
$507,000 is attributable to increased research and development expense of
$170,000 with the addition of a scientist and two technicians, increased sales
and marketing expense of $172,000 with the hiring of a director of marketing and
an assistant as well as increased commission costs associated with increased
sales, and net increases in general and administrative expenses totaling
$165,000.

     Management believes that the amount of research and development, sales and
marketing and general and administrative costs may increase as the Company
invests in long term growth and creates the necessary infrastructure to: achieve
its worldwide drug test marketing and sales goals, continue its penetration of
the direct sales market, reinforce its distributor based sales, and leverage new
product initiatives. However, management has implemented programs to control the
rate of increase of these costs to be more consistent with the expected sales
growth rate of the Company.

Research and development

         Research and development ("R&D") expenses for the six months ended June
30, 2003 were $339,000 or 5.8% of net sales compared to $169,000 or 3.4% of net
sales for the six months ended June 30, 2002. The increase in expense is
primarily due to several new positions added to the R&D group during 2002 and
the first quarter of 2003 and consulting fees offset by savings in project
development relating to a license fee for the saliva project expensed in 2002
which did not recur in 2003 and $60,000 of funding received in 2003 from
entities for which the Company performed R&D services, which offset current year
expense. A research scientist, along with two laboratory technicians were added
in late 2002 and the first quarter of 2003. These resources were added as part
of management's initiatives to: focus on new product development to meet the
changing needs of the on-site drug of abuse testing market, continue evaluation
of a potential "CLUB-DRUG" panel, develop test components for a HIV test
currently under development by an unrelated party, and develop new uses of
immunoassay lateral flow technology, specifically in the areas of veterinary
medicine and mycotoxin detection. The Company announced it had received FDA
510(k) clearance for its newly developed test for Propoxyphene and its Rapid Tec
3 and Rapid Tec 4 tests. Management expects increases in R&D expenses as it
explores new markets and uses for its immunoassay technology.


                                       10
<PAGE>

Selling and marketing expense

        Selling and marketing expense was $1,314,000 or 22.6% of net sales in
the first six months of 2003, an increase of $172,000, from $1,142,000 or 23.0%
of net sales in the same six months in 2002. This increase is primarily due to
additional commissions expense in sales and the hiring of a director of
marketing and marketing assistant in early 2003. This increased expense in
marketing has been made to support the Company's other efforts in penetrating
direct sales markets and reinforcing distributor sales. Increased spending in
advertisement, promotion, sales literature and trade show attendance has been
offset by savings in sales expense resulting from changes to the sales
commissions plan in late 2002 and early 2003.

General and administrative expense

        General and administrative expense was $165,000 higher in the first half
of 2003 than the same period in 2002. Total G&A expense in the first quarter of
2003 was $1,321,000 or 22.7% of net sales compared to $1,156,000 or 23.3% of net
sales in the first six months of 2002. Increases in personnel expense, directors
fees, insurance, accounting fees, licenses and permits, bad debts and office
travel offset by savings in legal fees, non cash compensation and postage
contributed to the increase in G & A expense. Increases in G&A expense are
commensurate with company growth. Further, expenses related to accounting fees,
the annual meeting, the annual report and some directors fees result from the
timing of these events in the current year and will not recur in the remainder
of 2003 to the extent they have occurred in the first six months.

Results of operations for the three months ended June 30, 2003 as compared to
the three months ended June 30, 2002

         Net sales were $3,171,000 for the three months ended June 30, 2003 as
compared to $2,710,000 for the three months ended June 30, 2002, representing an
increase of $461,000 or 17.0%. Direct sales, telemarketing sales and
international sales combined to contribute approximately $2,693,000 or 84.9% of
the net sales for the quarter compared to $1,932,000 or 71.3% in the second
quarter of 2002. During the three months ended June 30, 2003, the Company
continued its extensive program to market and distribute its primary product
lines, the Rapid Drug Screen and Rapid One, in addition to its saliva based
test, the Oralstat, and its recently developed Rapid Tec series.

         The Company continued its program of rebuilding relationships with key
distributors, executed agreements with several new distributors, expanded its
marketing, and continued the development of diagnostic tests or test components
using immunoassay lateral flow technology to diversify its product line into the
areas of veterinary medicine, mycotoxin detection, and tuberculosis. In
addition, components for an HIV test are being developed for an unaffiliated
third party and new drugs of abuse tests are being explored. Management believes
that sales from its urine based drug test kits and the OralStat saliva based
test will continue to grow as a result of this focus on the core business and
new sales will increase from new product development.

        Cost of goods sold for the three months ended June 30, 2003 was
$1,418,000 or 44.7% of net sales as compared to $1,226,000 or 45.2% of net sales
for the three months ended June 30, 2002. The increase in cost of goods sold is
commensurate with the increase in sales. Gross margins remained consistent at
55.3% in 2003 and 54.8% in 2002. The cost of labor and materials has remained
relatively consistent and the Company continued its efforts to control the costs
to produce their product.


                                       11
<PAGE>

         Operating expenses increased $249,000, or 20.1%, to $1,487,000 in first
three months of 2003 as compared to $1,238,000 in the same period in 2002. This
increase is attributable to increased research and development expenditures with
the addition of a scientist and two technicians, increased marketing expense
with the hiring of a director of marketing and an assistant, and net increases
in general and administrative expenses.

         Management believes that the amount of research and development, sales
and marketing and general and administrative costs may increase as the Company
continues its focus on long term growth and creates the necessary infrastructure
to: achieve its worldwide drug test marketing and sales goals, continue its
penetration of the direct sales market, reinforce its distributor based sales,
and leverage new product initiatives. However, management has implemented
programs to control the rate of increase of these costs to be more consistent
with the expected sales growth rate of the Company.

Research and development

        Research and development ("R&D") expenses for the three months ended
June 30, 2003 were $133,000 or 4.2% of net sales compared to $37,000 or 1.4% of
net sales for the three months ended June 30, 2002. R&D expense in the second
quarter of 2003 is net of $60,000 reclassified to cost of sales to match
revenues recognized for amounts received from entities for which the Company
performed R&D services. The increase in expense is primarily due to several new
positions added to the R&D group during 2002 and the first quarter of 2003. A
research scientist, along with two laboratory technicians were added in late
2002 and the first quarter of 2003. These resources were added as part of
management's initiatives to: focus on new product development to meet the
changing needs of the on-site drug of abuse testing market, continue evaluation
of a potential "CLUB-DRUG" panel, develop test components for a HIV test
currently under development by an unaffiliated third party, and develop new uses
of immunoassay lateral flow technology, specifically in the areas of veterinary
medicine and mycotoxin detection. Management expects increases in R&D expenses
as it explores new markets and uses for its immunoassay technology.

Selling and marketing expense

        Selling and marketing expense was $694,000 or 21.9% of net sales in the
second quarter of 2003, an increase of $86,000, from $608,000 or 22.4% of net
sales in the same three months in 2002. This increase is primarily due to
increases in commission costs associated with the increase in sales in the
current year as compared to 2002 and the hiring of a director of marketing and
marketing assistant in early 2003. This increased expense in marketing has been
made to support the Company's other efforts in penetrating direct sales and
reinforcing distributor sales. Increased spending in advertisement, promotion,
sales literature and trade show attendance has been offset by savings in sales
expense resulting from changes to the sales commissions plan in late 2002 and
early 2003.

General and administrative expense

        General and administrative expense was $67,000 higher in the second
quarter of 2003 than the same period in 2002. Total G&A expense in the second
quarter of 2003 was $660,000 or 20.8% of net sales compared to $593,000 or 21.9%
of net sales in the three months ended June 30, 2002. Contributing to the
increase in G & A expense were increases in personnel expense, directors fees
and expenses, accounting fees, travel, outside services and insurance costs
offset by savings in legal fees, non-cash compensation, and consulting fees.



                                       12
<PAGE>




LIQUIDITY AND CAPITAL RESOURCES AS OF JUNE 30, 2003

        The Company's cash requirements depend on numerous factors, including
product development activities, ability to penetrate the direct sales market,
market acceptance of its new products, and effective management of inventory
levels in response to sales forecasts. The Company expects to devote substantial
capital resources to continue its product development, expand manufacturing
capacity and continue research and development activities. The Company will
examine other growth opportunities including strategic alliances and expects
such activities will be funded from existing cash and cash equivalents, issuance
of additional equity or debt securities or additional borrowings subject to
market and other conditions. The Company believes that its current cash
balances, and cash generated from future operations will be sufficient to fund
operations for the next twelve months. If cash generated from operations is
insufficient to satisfy the Company's working capital and capital expenditure
requirements, the Company may be required to sell additional equity or obtain
additional credit facilities. There is no assurance that such financing will be
available or that the Company will be able to complete financing on satisfactory
terms, if at all.

         The Company has working capital of $3,106,000 at June 30, 2003 as
compared to working capital of $2,586,000 at December 31, 2002. The Company has
historically satisfied its net working capital requirements through cash
generated by proceeds from private placements of equity securities with
institutional investors. The Company has never paid any dividends on its common
shares and anticipates that all future earnings, if any, will be retained for
use in the Company's business and it does not anticipate paying any cash
dividends.

         Net cash used in operating activities was $33,000 for the six months
ended June 30, 2003 compared to net cash provided by operating activities of
$132,000 for the six months ended June 30, 2002. The net cash used in operating
activities for the six months ended June 30, 2003 was primarily due to and
increase in accounts receivable of $645,000, resulting from increased sales, an
increase in prepaid expenses of $42,000, primarily due to increased insurance
costs, and decreases in accounts payable and accrued expenses of $186,000 and
$11,000 respectively. These uses were partially offset by a decrease in
inventory of $374,000, resulting from increased sales and continued efforts to
control inventory levels, depreciation of $90,000 and net income of $417,000.

         Net cash provided by investing activities was $27,000 for the six
months ended June 30, 2003 compared to net cash used in investing activities of
$43,000 for the six months ended June 30, 2002. The net cash provided by
investing activities in the second quarter of 2003 was comprised of proceeds
from the sale of approximately 85 acres of land at the Company's headquarters in
Kinderhook, NY totaling $150,000, offset by $123,000 for the purchase of
property, plant and equipment.

         Net cash used in financing activities was $24,000 for the six months
ended June 30, 2003, consisting of capital lease and debt payments totaling
$89,000 offset by proceeds from the Company's line of credit totaling $40,000
and receipt of a $25,000 grant from the Columbia Economic Development
Corporation ("CEDC"). The CEDC grant is convertible to a loan payable to the
CEDC should the number of employees at the Company's Kinderhook, NY facility
fall below an established minimum. The loan would be based on a percentage of
the total grant outstanding beginning with 100% if the number of employees drops
below the established minimum at any time before 2004. Beginning in 2004 the
percentage that would be repayable to the CEDC is reduced by 10% for each
calendar year during which the number remains above the established threshold
(i.e., 90% in 2004, 80% in 2005, etc).

         At June 30, 2003 and 2002, the Company had cash and cash equivalents of
$201,000 and $537,000, respectively.


                                       13
<PAGE>

         The Company's primary short-term capital and working capital needs
relate to continued support of its research and development programs, opening
new distribution opportunities, focusing sales efforts on segments of the drugs
of abuse testing market that will yield high volume sales, increasing its
manufacturing and production capabilities, and establishing adequate inventory
levels to support expected sales.

DISCLOSURE CONTROLS AND PROCEDURES

         On July 25, 2003, the Company's CEO and CFO reviewed the Company's
disclosure controls and procedures. Based on this evaluation, the Company,
including the CEO and CFO, have concluded that the Company's disclosure controls
and procedures are adequate to ensure the clarity and material completeness of
the Company's disclosure in its periodic reports required to be filed with the
SEC. Additionally, based upon this most recent evaluation, we have concluded
that there were no significant changes in internal controls or other factors
that could significantly affect the internal controls of the company subsequent
to the date of evaluation.




                                       14
<PAGE>



                                     PART II

                                OTHER INFORMATION


Item 1. Legal Proceedings:

         None

Item 2. Changes in Securities

         None.

Item 3. Defaults upon Senior Securities

         None.

Item 4. Submission of Matters to a Vote of Security-Holders

         The following matters were voted upon at the Company's Annual Meeting
of Shareholders (the "Meeting") held at the Marriott Hotel in Albany, New York
on June 18, 2003.


                       PROPOSAL 1 - ELECTION OF DIRECTORS



Total shares voted: 20,346,463                Outstanding shares: 20,609,548
Percent of shares voted: 98.7

<TABLE>
<CAPTION>


              Director                 For             Pct.             Withheld       Pct.
              --------                 ---             ---              --------       ---
<S>                                 <C>                <C>             <C>              <C>
         Stan Cipkowski             18,552,060         91.2            1,794,403        8.8
         Edmund Jaskiewicz          18,567,095         91.3            1,779,368        8.7
         Gerald Moore               19,422,589         95.5              923,874        4.5
         D. Joseph Gersuk           13,489,047         66.3            6,857,416       33.7
         Denis O'Donnell, M.D.      13,488,297         66.3            6,858,166       33.7
         Dr. Gerald W. Lynch        17,484,134         85.9            2,862,329       14.1
         Daniel W. Kollin           19,456,889         95.6              889,574        4.4
</TABLE>

All seven nominees for election to the Board of Directors were elected.

     PROPOSAL 1 - RATIFICATION OF THE APPOINTMENT OF PRICEWATERHOUSECOOPERS
    LLP AS THE INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDED
                                DECEMBER 31, 2003

                  For:        20,274,572    or       99.6%
                  Against:        21,580    or        .06%
                  Abstain:        50,311    or         .4%

Item 5.  Other Information

         None.


                                       15
<PAGE>

Item 6.  Exhibits and Reports on Form 8-K

      (a)  Exhibits

                   99.1    Certification of the Chairman of the Board and Chief
                           Executive Officer pursuant to 18 U.S.C. Section 1350,
                           as adopted pursuant to Section 906 of the
                           Sarbanes-Oxley Act of 2002.

                   99.2    Certification of the Chief Financial Officer pursuant
                           to 18 U.S.C. Section 1350, as adopted pursuant to
                           Section 906 of the Sarbanes-Oxley Act of 2002.

      (b) Reports on Form 8-K

                  On June 23, 2003, the Company filed a Form 8-K related to the
          resignation of D. Joseph Gersuk from the Company's Board of Directors.

                  On July 1, 2003, the Company filed a Form 8-K related to the
          resignation of Stan Cipkowski as an Executive Vice President of the
          Company.




                                       16
<PAGE>


                                   SIGNATURES



     In accordance with the requirements of the Exchange Act, the registrant has
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.




                                 AMERICAN BIO MEDICA CORPORATION
                                 (Registrant)

                                 By: /s/Keith E. Palmer
                                 --------------------------------------------
                                 EVP of Finance, Chief Financial Officer and
                                 Treasurer (Principal Accounting Officer and
                                 duly authorized Officer)


Dated: August 12, 2003




                                       17




<PAGE>

CERTIFICATIONS


I, Gerald A. Moore, certify that:


1. I have reviewed this quarterly report on Form 10-QSB of American Bio Medica
Corporation;


2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;


3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;


4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:


a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;


b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and


c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;


5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):


a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and


b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and


6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: August 12, 2003


                                                   /s/ Gerald A. Moore
                                                   ----------------------------
                                                   Gerald A. Moore
                                                   Chairman, CEO and President


                                       18
<PAGE>



CERTIFICATIONS


I, Keith E. Palmer, certify that:


1. I have reviewed this quarterly report on Form 10-QSB of American Bio Medica
Corporation;


2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;


3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;


4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:


a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;


b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and


c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;


5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):


a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and


b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and


6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: August 12, 2003


                                 /s/ Keith E. Palmer
                                 -------------------------
                                 Keith E. Palmer
                                 Chief Financial Officer
                                 and Vice President



                                       19